Intellectual property related to the Australian Life Sciences sector

Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (3 October 2017)

The US Patent Office issues new patents every Tuesday. Australian assignees generally get two or three healthcare and biotech-related patents a week while New Zealand assignees get one every three or four weeks.

Australian grants

Here are the 140 US patents relevant to Australia's Life Sciences sector that were granted in 2015, for an issuance rate of 2.7 per week:

US Patent 9,221,799, Anti-cancer agents, Walter and Eliza Hall Institute, 29 December 2015
US Patent 9,220,928, Plant extracts from Acronychia species and their use, EcoBiotics, 29 December 2015
US Patent 9,220,806, Biocompatible material and uses thereof, University of Sydney, 29 December 2015
US Patent 9,220,724, MicroRNA-based approach to treating malignant pleural mesothelioma, Asbestos Diseases Research Institute, 29 December 2015
US Patent 9,220,678, Coating method, University of Queensland, 29 December 2015
US Patent 9,211,331, Mineral based composition and methods of use, Tuffrock, 15 December 2015
US Patent 9,211,329, Method of treating inflammatory bowel disease, CSL Ltd (ASX: CSL), 15 December 2015
US Patent 9,211,237, Film foaming hydroalcoholic foam, Stiefel Research Australia, 15 December 2015
US Patent 9,206,171, 6-{2 -[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzi- soxazole bis-dihydrogenphosphate salt (1:2), Biota, 8 December 2015
US Patent 9,205,121, Echinacea formulation, Integria Healthcare, 8 December 2015
US Patent 9,200,020, 6-oxopurine phosphoribosyltransferase inhibitors, University of Queensland with the Institute of Organic Chemistry and Biochemistry (Czechia), 1 December 2015
US Patent 9,199,976, Haematopoietic-prostaglandin D2 synthase inhibitors, University of Queensland, 1 December 2015
US Patent 9,193,716, S1P receptors modulators and their use thereof, Akaal Pharma, 24 November 2015
US Patent 9,193,793, Antibodies against G-CSFR and uses thereof, CSL Ltd, 24 November 2015
US Patent 9,186,404, Brain, spinal and nerve injury treatment, Eustralis Pharmaceuticals, 17 November 2015
US Patent 9,186,321, Oral spray formulations and methods for administration of sildenafil, Suda Ltd (ASX: SUD), 17 November 2015
US Patent 9,181,320, Peptides for generating an antibody selectively binding to a non-ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor, Biosceptre International, 10 November 2015
US Patent 9,180,194, Method and composition for transdermal drug delivery, Acrux (ASX: ACR), 10 November 2015
US Patent 9,175,279, Method of purifying factor VII and/or factor VIIa, CSL Ltd (ASX: CSL), 3 November 2015
US Patent 9,174,982, Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases, Walter and Eliza Hall Institute with AbbVie (US) and Genentech (US), 3 November 2015
US Patent 9,173,911, Method for producing vegetable cell sap concentrate and means for the production thereof, Solagran with SibEX (Russia), 3 November 2015
US Patent 9,173,866, Compositions and products containing R-equol, and methods for their making, Sanitarium with Cincinnati Children's Hospital (US), 3 November 2015
US Patent 9,169,495, Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells, EnGeneIC, 27 October 2015
US Patent 9,169,329, Antibodies directed to the receptor tyrosine kinase c-Met, Monash University with the Ludwig Institute for Cancer Research (US), 27 October 2015
US Patent 9,169,211, 8-hydroxy quinoline derivatives, Prana Biotechnology (ASX: PBT), 27 October 2015
US Patent 9,168,302, Reduction of side effects from aromatase inhibitors used for treating breast cancer, Chavah Pty Ltd , 27 October 2015
US Patent 9,168,216, Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof, Phosphagenics (ASX: POH), 27 October 2015
US Patent 9,163,081, Antibody recognizing C-domain of midkine, Cellmid (ASX: CDY), 20 October 2015
US Patent 9,163,029, Substituted imidazo[1,2-a]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections, Biota, 20 October 2015
US Patent 9,163,018, Method of treatment of age-related macular degeneration (AMD), Prana Biotechnology (ASX: PBT), 20 October 2015
US Patent 9,162,985, Salts and solvates of a tetrahydroisoquinoline derivative, Spinifex Pharmaceuticals, 20 October 2015
US Patent 9,161,923, Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease, Brian Holden Vision Institute, 20 October 2015
US Patent 9,161,562, Natural sweetener, Horizon Science Pty Ltd (David Kannar and Barry Kitchen), 20 October 2015
US Patent 9,157,054, Device and method for preparing microparticles, University of Queensland, 13 October 2015
US Patent 9,156,916, Modulation of T helper cell-mediated immune responses, University of Sydney withNorthern Sydney and Central Coast Area Health Service, 13 October 2015
US Patent 9,156,855, Regulation of nitric oxide release and biofilm development, University of New South Wales with University of Wollongong, 13 October 2015
US Patent 9,155,760, Method of prophylaxis of bacterial vaginosis, Starpharma, 13 October 2015
US Patent 9,150,621, Mutant bacterial glycoproteins and uses thereof, University of Queensland, 6 October 2015
US Patent 9,150,619, Method of elicting or inducing an immune response, CSL Ltd (ASX: CSL) with University of Melbourne, 6 October 2015
US Patent 9,149,452, Methods and compositions for promoting the neurological development of an infant, Women's & Children's Health Research Institute, 6 October 2015
US Patent 9,145,375, Quinazolinone compounds, Prana Biotechnology (ASX: PBT), 29 September 2015
US Patent 9,139,879, TAM receptors and TAM receptor ligands in detection and modulation of neuropathological disease, Florey Institute of Neuroscience and Mental Health, 22 September 2015
US Patent 9,134,311, Methods and compositions for treating and preventing malaria using an invasion ligand directed to a protease-resistant receptor, Walter and Eliza Hall Institute, 15 September 2015
US Patent 9,133,188, Methods for preparing naphthyridines, Bionomics (ASX: BNO), 15 September 2015
US Patent 9,131,681, Particles comprising a releasable dopant therein, Australian Nuclear Science & Technology Organisation, 15 September 2015
US Patent 9,127,130, Polylysine dendrimer contrast agent, Starpharma (ASX: SPL) with Baker IDI Heart and Diabetes Institute, 8 September 2015
US Patent 9,127,057, Anti-IL-23 heterodimer specific antibodies, Teva Pharmaceuticals Australia, 8 September 2015
US Patent 9,125,943, Reconstituted HDL formulation, CSL Ltd (ASX: CSL), 8 September 2015
US Patent 9,125,853, Treatment or prevention of infection, Oral Health CRC, 8 September 2015
US Patent 9,122,778, Methods of treating diseases, Biotempus, 1 September 2015
US Patent 9,120,775, Viral polymerase inhibitors, Biota, 1 September 2015
US Patent 9,119,833, Administration of relaxin to treat nephrogenic diseases of water imbalance involving acquaporin-4, University of Melbourne with University of Florida, 1 September 2015
US Patent 9,119,818, Use of angiogenin or angiogenin agonists for treating diseases and disorders, Murray Goulburn Co-Operative with Agriculture Victoria Services, 1 September 2015
US Patent 9,119,805, Therapy and prevention of problem drinking, University of Sydney, 1 September 2015
US Patent 9,119,394, Anti-microbial polymers and their compositions, Recce (ASX: RCE), 1 September 2015
US Patent 9,115,363, Gene expression and eradication system in Helicobacter pylori, Ondek, 25 August 2015
US Patent 9,110,061, Use of amino acid sequences from Mycobacterium tuberculosis or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom, Cellestis, 18 August 2015
US Patent 9,109,040, Treatment and prevention of malaria, Walter and Eliza Hall Institute, 18 August 2015
US Patent 9,107,811, Composition for treating skin lesions, Sci-Chem International Pty Ltd, 18 August 2015
US Patent 9,101,732, Drug-delivery accessory for an implantable medical device, Cochlear (ASX: COH), 11 August 2015
US Patent 9,101,650, Treatment of bone marrow edema (oedema) with polysulfated polysaccharides, Paradigm Biopharma (ASX: PAR), 11 August 2015
US Patent 9,095,587, Methods and compositions for improved nerve conduction velocity, Spinifex Pharmaceuticals, 4 August 2015
US Patent 9,095,524, Customized compositions and uses thereof, Bond University, 4 August 2015
US Patent 9,095,519, Dosage form containing two or more active pharmaceutical ingredients in different physical forms, Alphapharm Pty Ltd, 4 August 2015
US Patent 9,090,706, Fibronectin: growth factor chimeras, Queensland University of Technology, 28 July 2015
US Patent 9,089,508, Method of transfection and compositions therefor, University of Melbourne, 28 July 2015
US Patent 9,085,770, Delivery of dsRNA to arthropods, Commonwealth Scientific and Industrial Research Organisation, 21 July 2015
US Patent 9,085,628, Antibody molecule for human GM-CSF receptor alpha, CSL Ltd (ASX: CSL) with Medimmune (US), 21 July 2015
US Patent 9,084,827, Biodegradable polyurethane/urea compositions, Polynovo (ASX: PNV), 21 July 2015
US Patent 9,084,770, Modulation of insulin like growth factor I receptor expression in cancer, Antisense Therapeutics (ASX: ANP), 21 July 2015
US Patent 9,079,967, Modified chaperonin 10, Invion (ASX: IVX), 14 July 2015
US Patent 9,079,950, Modified Hepatitis C virus proteins, Burnet Institute, 14 July 2015
US Patent 9,078,845, Anti-microbial agent, Kayban Pty Ltd, 14 July 2015
US Patent 9,078,816, Buccal, polar and non-polar spray containing ondansetron, Suda Ltd (ASX: SUD), 14 July 2015
US Patent 9,078,810, Transdermal delivery system, Acrux (ASX: ACR), 14 July 2015
US Patent 9,073,997, Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis, Opthea (ASX: OPT), 7 July 2015
US Patent 9,066,982, Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells, EnGeneIC, 30 June 2015
US Patent 9,066,919, Hyaluronan as a chemo-sensitizer in the treatment of cancer, Alchemia (ASX: ACL), 30 June 2015
US Patent 9,066,526, Allergy treatment using acid treated aqueous whey protein extract, Dairy Australia, 30 June 2015
US Patent 9,063,155, Immunotherapeutic method of treating neoplastic conditions, Medvet Science Pty Ltd, 23 June 2015
US Patent 9,062,288, Therapeutic methods using adipose tissue-derived cell suspensions comprising adipocytes, Regeneus (ASX: RGS), 23 June 2015
US Patent 9,062,118, J-superfamily conotoxin peptides, University of Queensland with University of Utah (US) and the Max Planck Society (Germany), 23 June 2015
US Patent 9,062,013, Positive allosteric modulators of the alpha.7 nicotinic acetylcholine receptor and uses thereof, Bionomics (ASX: BNO), 23 June 2015
US Patent 9,062,013, Chimeric relaxin polypeptides comprising an A and B chain derived from different relaxin family peptides, Florey Institute of Neuroscience and Mental Health, 16 June 2015
US Patent 9,051,551, Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors, University of Western Australia, 9 June 2015
US Patent 9,051,369, Avian cytokines and genetic sequences encoding same, Commonwealth Scientific and Industrial Research Organisation, 9 June 2015
US Patent 9,045,475, Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases, Walter and Eliza Hall Institute with AbbVie (US) and Genentech (US), 2 June 2015
US Patent 9,045,452, Antimicrobial and radioprotective compounds, BioDiem, 2 June 2015
US Patent 9,044,489, Medicinal compositions containing honey, Medihoney Pty Ltd, 2 June 2015
US Patent 9,040,503, Medicinal carbohydrates for treatment of respiratory conditions, Aus Bio Ltd, 26 May 2015
US Patent 9,035,028, Temperature sensitive conjugate compositions, Baker IDI Heart and Diabetes Institute with Emory University (US), 19 May 2015
US Patent 9,034,381, Process to control particle size, Alphapharm Pty Ltd, 19 May 2015
US Patent 9,034,378, Biodegradable polyurethane and polyurethane ureas, PolyNovo (ASX: PNV), 19 May 2015
US Patent 9,023,892, Antimicrobial compounds, Ramiz Boulos, 5 May 2015
US Patent 9,023,863, Fatty acid pharmaceutical foam, Stiefel Research Australia, 5 May 2015
US Patent 9,023,799, Method to reduce loss of cardiac function following ischemia/reperfusion, Cellmid (ASX: CDY), 5 May 2015
US Patent 9,018,247, Compositions and products containing S-equol, and methods for their making, Sanitarium with Cincinnati Children's Hospital (US), 28 April 2015
US Patent 9,018,207, Method of treatment or prophylaxis, Spinifex Pharmaceuticals, 28 April 2015
US Patent 9,018,168, Therapeutic method for treating congestive heart failure, Madeleine Pharmaceuticals, 28 April 2015
US Patent 9,017,697, Compositions and methods for modulating immune responses, University of Queensland, 28 April 2015
US Patent 9,017,643, Particles comprising a releasable dopant therein, Australian Nuclear Science & Technology Organisation, 28 April 2015
US Patent 9,012,461, FAK inhibitors, Cancer Therapeutics CRC Pty Ltd, 21April, 2015
US Patent 9,011,878, Vaccine strains of Brachyspira hyodysenteriae, Spirogene Pty Ltd, 21 April 2015
US Patent 9,006,397, FN14 binding proteins and uses thereof, TransBio, 14 April 2015
US Patent 9,006,284, Combination therapy for treating proliferative diseases, Bionomics (ASX: BNO), 14 April 2015
US Patent 9,006,200, MicroRNA-based approach to treating malignant pleural mesothelioma, Asbestos Diseases Research Institute, 14 April 2015
US Patent 8,999,920, Reconstituted high density lipoprotein formulation and production method thereof, CSL Ltd (ASX: CSL), 7 April 2015
US Patent 8,999,353, Method of eliciting an immune response against pandemic influenza virus, CSL Ltd (ASX: CSL), 7 April 2015
US Patent 8,993,635, Method of increasing or maintaining the reproductive performance of sows, Pork CRC, 31 March 2015
US Patent 8,993,520, Method and composition for transdermal drug delivery, Acrux (ASX: ACR), 31 March 2015
US Patent 8,992,986, Controlled release of biological entities, Australian Nuclear Science & Technology Organisation, 31 March 2015
US Patent 8,992,982, Formulation of indomethacin, iCeutica, 31 March 2015
US Patent 8,992,935, Means of controlling infection persistence of Helicobacter pylori , Ondek, 31 March 2015
US Patent 8,986,700, Immunogenic lipopeptides comprising T-helper and cytotoxic T-lymphocyte (CTL) epitopes, Queensland Institute of Medical Research, 24 March 2015
US Patent 8,980,914, Therapeutic agent for chronic obstructive pulmonary disease and method for treatment for chronic obstructive pulmonary disease with the same, Mariposa Health, 17 March 2015
US Patent 8,975,278, 8-hydroxy quinoline derivatives, Prana Biotechnology (ASX: PBT), 10 March 2015
US Patent 8,975,245, Anaesthetic formulation, Drawbridge Pharmaceuticals, 10 March 2015
US Patent 8,974,803, Injectable biomaterials, University of Sydney, 10 March 2015
US Patent 8,968,731, Treatment of uveitis, CSL Ltd (ASX: CSL), 3 March 2015
US Patent 8,962,830, Protein kinase inhibitors and methods of treatment, Walter and Eliza Hall Institute, 24 February 2015
US Patent 8,962,801, Neisseria porin proteins, Griffith University, 24 February 2015
US Patent 8,962,649, Multidose package, course and method of treatment for delivering predetermined multiple doses of a pharmaceutical, iNova Pharmaceuticals, 24 February 2015
US Patent 8,960,128, Topical anesthetic composition, Animal Ethics Pty Ltd, 24 February 2015
US Patent 8,957,099, Treatment of ADHD, Gosforth Clinic (Dr Philip Bird), 17 February 2015
US Patent 8,956,864, Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells, EnGeneIC, 17 February 2015
US Patent 8,952,157, Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases, AbbVie and Walter and Eliza Hall Institue of Medical Research, 10 February 2015
US Patent 8,951,543, Nano silver--zinc oxide composition, Polymers CRC, 10 February 2015
US Patent 8,946,381, Compositions and uses thereof for the treatment of wounds, Phylogica (ASX: PYC) and the McComb Foundation, 3 February 2015
US Patent 8,946,146, Method for modulating appetite, St Vincent's Hospital Sydney., 3 February 2015
US Patent 8,945,551, Biopolymer hybrid gel-depot delivery system, Polymers CRC, 3 February 2015
US Patent 8,940,695, Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy, Opthea (ASX: OPT), 27 January 2015
US Patent 8,939,932, Inactivation of papillomavirus, Dr Jenny McCloskey, 27 January 2015
US Patent 8,937,052, Therapeutic protocols using hyaluronan, Alchemia (ASX: ACL), 20 January 2015
US Patent 8,933,092, Methods and compositions comprising sequential administration opioid receptor agonists, QRXPharma, 13 January 2015
US Patent 8,933,033, Chaperonin 10 variants, Invion (ASX: IVX), 13 January 2015
US Patent 8,933,027, Method of treating a disease or condition characterised by aberrant epithelial cell proliferation, Queensland University of Technology, 13 January 2015
US Patent 8,932,588, Treatment of cancer involving mutated KRAS or BRAF genes, Teva Pharmaceuticals Australia, 13 January 2015
US Patent 8,927,575, Salts and solvates of a tetrahydroisoquinoline derivative, Spinifex Pharmaceuticals, 6 January 2015
US Patent 8,927,565, Compositions for veterinary and medical applications, Aus Bio Ltd, 6 January 2015
US Patent 8,927,503, Modulations of protease activated receptors, University of Queensland, 6 January 2015

New Zealand applications

Here are the 12 US patents relevant to New Zealand's Life Sciences sector that were granted in 2015, for an issuance rate of 0.2 applications per week:

US Patent 9,212,204, Treatment of Rett Syndrome using glycyl-L-2-methylprolyl-L-glutamic acid, Neuren Pharmaceuticals (ASX: NEU), 15 December 2015
US Patent 9,198,430, Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation, Bayer New Zealand, 1 December 2015
US Patent 9,119,851, Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals, Neuren Pharmaceuticals (ASX: NEU), 1 September 2015
US Patent 9,102,743, Immunogenic polypeptide isolated from Mycobacterium avium subspecies paratuberculosis and uses thereof, Massey University with Institut Pasteur (France), 11 August 2015
US Patent 9,101,632, Kinase inhibitors, prodrug forms thereof and their use in therapy, Auckland UniServices (University of Auckland), 11 August 2015
US Patent 9,095,430, Biomaterials with enhanced properties and devices made therefrom, Southern Lights Ventures, 4 August 2015
US Patent 9,079,859, Synthetic lethal targeting of glucose transport, Auckland UniServices (University of Auckland) with Stanford University (US) and Ruga Corp (US), 14 July 2015
US Patent 9,073,916, Prodrug forms of kinase inhibitors and their use in therapy, Auckland UniServices (University of Auckland), 7 July 2015
US Patent 9,045,505, Nitric oxide donors, University of Otago and Medical Research Council (UK), 2 June 2015
US Patent 9,040,485, Synthetic analogues of neural regeneration peptides, CuroNZ, 26 May 2015
US Patent 8,993,019, Emulsion, Massey University, 31 March 2015
US Patent 8,987,244, Preventing and/or treating cardiovascular disease and/or associated heart failure, PhilERA (Professor Garth Cooper), 24 March 2015